Investors

Investor Overview

Synta Overview
Synta Pharmaceuticals is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. ... More >>
Recent NewsMore >>
DateTitle 
04/16/15Synta Announces Presentations at the 2015 Annual Meeting of the American Association of Cancer Research
LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 16, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that poster presentations related to studies with ganetespib, a novel, potent small molecule inhibitor of heat shock protein 90 (Hsp90) in Phase 3 development, and STA-12-8666, the company’s leading candidate from its proprietary Hsp90 inhibitor Drug Conjugate (HDC) Program, will be presented at the 2015 Annual Meeting of the American Association... 
Printer Friendly Version
04/06/15Synta Pharmaceuticals Closes Public Offering of Common Stock
LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 6, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today the closing of its underwritten public offering of 25,300,000 shares of common stock, including 3,300,000 shares sold pursuant to the full exercise of the option to purchase additional shares previously granted to the underwriters, at a public offering price of $1.75 per share. Gross proceeds to Synta are approximately $44.3 million, before deduct... 
Printer Friendly Version
03/31/15Synta Pharmaceuticals Prices Public Offering of Common Stock
LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 31, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that it has priced an underwritten public offering of 22,000,000 shares of its common stock at a price to the public of $1.75 per share. Gross proceeds to Synta are expected to be approximately $38.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Synta. The offering is expected to c... 
Printer Friendly Version
03/30/15Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock
LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 30, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it has commenced an underwritten public offering of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Synta intends to grant the underwriters a 30-day option to purchase addit... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
SNTA (Common)
ExchangeNASDAQ (US Dollar)
Price$2.93
Change (%) Stock is Down 0.1 (3.30%)
Volume2,276,982
Data as of 04/17/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Synta 2014 Form 10-K